<DOC>
	<DOC>NCT01037192</DOC>
	<brief_summary>Our hypothesis is that large-dose, extended-interval vancomycin (30 mg/kg IV q24h) administration provides non-inferior clinical efficacy and microbiological efficacy to standard vancomycin (15 mg/kg IV q12h) administration for skin and soft tissue infections in an outpatient setting.</brief_summary>
	<brief_title>Evaluating the Use of Large-dose, Extended Interval Vancomycin Intravenous Administration for Skin and Soft Tissue Infections</brief_title>
	<detailed_description />
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>Soft Tissue Infections</mesh_term>
	<mesh_term>Vancomycin</mesh_term>
	<criteria>Age 19 to 70 years Weight 40 80 kg Suspected or confirmed skin or soft tissue infection for which vancomycin is indicated Subject referred to or admitted into OPAT by an Infectious Disease Specialist or Emergency Physician Subject able to provide informed consent Known history of allergy to vancomycin Pregnancy Granulocytopenia (&lt; 1x109/L) Renal impairment (serum creatinine &gt; 177 Âµmol/L or eGFR &lt; 50 mL/min) Known history of vestibular disease or hearing loss Subjects treated with vancomycin within the previous month Subjects who have received more than 24 hours of vancomycin Subjects receiving other antimicrobials that cover MRSA (e.g. cotrimoxazole, rifampin, linezolid)</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>August 2015</verification_date>
	<keyword>outpatient</keyword>
	<keyword>skin and soft tissue infections</keyword>
	<keyword>vancomycin intravenous</keyword>
</DOC>